In the case reported here, hepatic hematoma developed after administration of tissue plasminogen activator (alteplaz) in a 51 years old man with acute anterior myocardial infartion.
📌 3 Key Takeaways
🎯
Objective & Hypothesis:The major complication of thrombolytic treatment is hemorrhage, including gingival bleeding, gastrointestinal bleeding, hematuria, especially intraperitoneal bleeding and intracranial bleeding which may be life-threatening.
📊
Key Findings & Data:The major complication of thrombolytic treatment is hemorrhage, including gingival bleeding, gastrointestinal bleeding, hematuria, especially intraperitoneal bleeding and intracranial bleeding which may be life-threatening.
💡
Conclusion & Impact:In the case reported here, hepatic hematoma developed after administration of tissue plasminogen activator (alteplaz) in a 51 years old man with acute anterior myocardial infartion.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters
Abstract
The major complication of thrombolytic treatment is hemorrhage, including gingival bleeding, gastrointestinal bleeding, hematuria, especially intraperitoneal bleeding and intracranial bleeding which may be life-threatening. In the case reported here, hepatic hematoma developed after administration of tissue plasminogen activator (alteplaz) in a 51 years old man with acute anterior myocardial infartion.
Özet
Trombolitik tedavinin majör komlikasyonu kanamadır. Diş eti kanaması, gastrointestinal kanama, hematüri gibi kanamalar olabileceği gibi hayatı tehdit edebilen intrakranyal ve intraabdominal kanamalar da görülebilmektedir. Bu olgu sunumunda akut anteriyor miyokard enfarktüsü geçiren, doku plazminojen aktivatörü (alteplaz) verilmesinden sonra karaciğer hematomu gelişen 51 yaşında erkek hasta sunulmaktadır.
🔖
Cite This Article
BAYRAM, N. A., AKDİ, A., KELEŞ, T., DURMAZ, T., AKÇAY, M., BOZKURT, E. (2010). Liver haematoma after administration of thrombolytic therapy case report. MN Kardiyoloji, Cilt: 17 - Sayı: 5, 326–328. https://ajindex.com/articles/297462
Rosamond W, Flegal K, Friday G, et al. Heart disease and stroke statistics -2007 update: a report from the Ame - rican Heart Association Statistics Committee and Stroke Statistics Subcommitee. Circulation 2007;115: e69-171
Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA Guidelines for the Management of Patients With STElevation Myocardial Infartion-executive summary. Circulation 2004;110:588-636 3. A comparison of reteplase with alteplase for acute myocardial infarction. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO-III) Investigators. N Engl J Med 1997;337:1118-23 4. Ismal A. Cole JP. Subcabsular hepatic and inraperitoneal bleed after administration of tissue plasminogen activator in a patient with acute myocardial infarction. Heart Dis 2000;2:13-5 5. S Akay, O Dikme. Hepatic haemorrhage after thrombolytic administration in a patient with myocardial infarction who had a trauma: are we missing something? Emerg Med J 2008;25:237-8 6. Tomescu D, Vişan A, Popescu I, Tulbure D. Liver rupture of subcapcular haematoma after pharmacologic revascularization (Streptokinase) for acute myocardial infarctioncase report. Chirurgia (Bucur) 2008;103:577-82 7. Willis SM, Bailey SR. Streptokinase-induced subcapsular hematoma of the liver. Arch Intern Med. 1984;144: 2084-5
Gárcia-Jiménez A, Castro Mao M, Freire Moán D, Otero Ferreiro S, Gomez Gutiérrez M, Marini Diáz M, Gonzalez Fernández JM. Hepatic bleeding and hemorrhagic shock following thrombolytic therapy in patients with acute myocardial infarction. Chest. 1997;111:1787.